African Journal of Medicine and Pharma Research
E-ISSN: 2992-4197; P-ISSN: 2992-4170
https://africanjmpr.com/
Volume-1, Issue-1, 2023: 35-36

Essay Article

So, What After Corona?

Majid Mohammed Mahmood

Department of Biology, College of Science, Mustansiriyah University, Baghdad, Iraq
Email: majidmahmood93@yahoo.com

Received: May 11, 2023 **Accepted:** June 10, 2023 **Published:** June 26, 2023

The life of individuals with health ailments here and there is not the same as life without them. People, in a way, experience health problems, whether known or unknown (permanent or temporary), in various parts of the body years after getting COVID-19. These ongoing health problems are sometimes called post-COVID-19 syndrome, post-COVID conditions, or sequelae of the SARS-COV-2 infection. Every system in the body has angiotensin converting enzyme 2 (ACE2) receptors, which the SARS-CoV-2 virus attaches to and can negatively impact (1). The virus itself had actions that affected the nervous system (2), the circulatory system, the heart (3), the kidneys (4), and the lung: with (5) and without (6) micro-fibrosis foci in the lungs. The side effects left by those pathological events, as well as the side effects caused by the use of COVID-19 vaccines in their various forms (7), at the level of the circulatory system and the heart, as well as on the nervous system, not to mention hidden events whose exact details and dimensions we did not yet realize. Equally important to all of this, if not more so, is what might occur in terms of changes to the genetic makeup of those who contract the disease, receive a vaccination, or both. In order to save what can be saved, it is now imperative that scientific effort be concentrated more quickly. Pharmaceutical companies are also invited here to provide corrective and therapeutic materials that minimize or eliminate from the body as much as possible these effects or other consequences linked to contemporary living in order to lessen the severity of the harm to general health.

In our opinion, Coronavirus will ultimately behave as an opportunistic virus that will occur more often or be more severe in people with weakened immune systems than in people with healthy immune systems. It is possible that Coronavirus vaccines will be limited to groups that need special protection, such as those who suffer from immunodeficiency or those who are taking immunosuppressive drugs.

Declarations
Acknowledgments: Not applicable.
Conflict of Interest: None.
Financial Assistance: None.
Ethical Approval: Not required.
Informed Consent: Not applicable.
Author Contribution: The author confirms sole responsibility for study conception and manuscript preparation.

References

1. Jain U. Effect of COVID-19 on the Organs. Cureus. 2020;12(8):e9540.
2. Helms J, Kremer S, Merdji H, Clere-Jehl R, Schenck M, Kummerlen C, Collange O, Boulay C, Fafi-Kremer S, Ohana M, Anheim M. Neurologic features in severe SARS-CoV-2 infection. New Eng J Med. 2020;382(23):2268-70.
3. Nahum J, Morichau-Beauchant T, Daviaud F, Echegut P, Fichet J, Maillet JM, Thierry S. Venous thrombosis among critically ill patients with coronavirus disease 2019 (COVID-19). JAMA Netw Open. 2020;3(5):e2010478.
4. Puelles VG, Lütgehetmann M, Lindenmeyer MT, Sperhake JP, Wong MN, Allweiss L, Chilla S, Heinemann A, Wanner N, Liu S, Braun F et al. Multiorgan and renal tropism of SARS-CoV-2. New Eng J Med. 2020;383(6):590-2.

5. Copin MC, Parmentier E, Duburcq T, Poissy J, Mathieu D. Time to consider histologic pattern of lung injury to treat critically ill patients with COVID-19 infection. Intensive Care Med. 2020;46:1124-6.
6. Xu Z, Shi l, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8:420-22.
7. Hamed RM, Mahmood MM, Ad'hiah AH. The abundance of Interleukin-22, 37, and 38 post-vaccination and following COVID-19 recuperation. J Popul Therapeu Clin Pharmacol. 2023;30(3):505-14.

Citation: Mahmood MM. So, What After Corona?. Afr J Med Pharm Res. 2023;1(1):35-36.